Rapamycin was responded well in cancer cells harboring PIK3CA and/or PTEN mutations (P = 0.0123) in a preclinical study, and inhibited tumor volume and microvasculature growth when was applied in a mouse xenograft model [145,146]. Here, PIK3CA is linked to neoplasm.